Halter Ferguson Financial Inc. Sells 135,896 Shares of MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA)

Halter Ferguson Financial Inc. cut its position in shares of MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIAFree Report) by 36.1% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 240,818 shares of the company’s stock after selling 135,896 shares during the quarter. MAIA Biotechnology makes up about 0.2% of Halter Ferguson Financial Inc.’s investment portfolio, making the stock its 22nd largest position. Halter Ferguson Financial Inc. owned 0.92% of MAIA Biotechnology worth $477,000 at the end of the most recent reporting period.

Separately, Geode Capital Management LLC increased its position in shares of MAIA Biotechnology by 22.9% during the 3rd quarter. Geode Capital Management LLC now owns 192,563 shares of the company’s stock valued at $541,000 after purchasing an additional 35,821 shares during the last quarter. Hedge funds and other institutional investors own 5.65% of the company’s stock.

MAIA Biotechnology Trading Up 7.7 %

MAIA opened at $1.67 on Tuesday. The stock’s 50 day moving average is $1.92. MAIA Biotechnology, Inc. has a 1 year low of $1.46 and a 1 year high of $5.99. The company has a market cap of $43.69 million, a price-to-earnings ratio of -1.21 and a beta of 0.20.

About MAIA Biotechnology

(Free Report)

MAIA Biotechnology, Inc, a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer.

Recommended Stories

Want to see what other hedge funds are holding MAIA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIAFree Report).

Receive News & Ratings for MAIA Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MAIA Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.